| Patient | Muhammad Ali |
|---|---|
| Date of birth | 1942-01-17 |
| Identifiers | MRN HR-BX001-SYN-TD; SSN (made up) 000-01-7724 |
| Document date | 1996-09-08 |
| Author | Celeste Moreau, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-month Parkinson's disease review. [S]
Mr. Ali returns six months after his first visit. He continues carbidopa-levodopa one and a half tablets three times a day before meals, with phone alarms, and has noticed no wearing-off, involuntary movements, or lightheadedness. He finished physical therapy and keeps up about 180 minutes a week of walking, stationary cycling, and balance exercises. He practices his voice exercises daily. He has had no falls. When asked about impulse control today, he reports no new urges to gamble, shop, or eat and no compulsive hobbies. He has not yet seen a dentist. [S]
| Element | Detail |
|---|---|
| Medicines | Levodopa 150 mg three times daily before meals; no side effects |
| Motor complications | None |
| Exercise | About 180 minutes a week |
| Falls | None in six months |
| Impulse control | No new urges or compulsive behaviors |
| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No lightheadedness on standing or fainting |
| Gastrointestinal | Negative | No constipation, nausea, or trouble swallowing |
| Neurological | Positive | Mild slowness and right-hand tremor, unchanged since the spring |
| Psychiatric | Negative | Mood good; no hallucinations or impulse-control problems |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Carbidopa-levodopa 25/100 mg oral tablet, one tablet by mouth three times daily | One tablet by mouth three times daily, at about 7 a.m., noon, and 5 p.m. | Oral route | 1984-10-01 to 1996-03-10 | completed | S |
| Carbidopa-levodopa 25/100 mg oral tablet, one and a half tablets by mouth three times daily, 30 minutes before meals | One and a half tablets (levodopa 150 mg) by mouth three times daily, 30 minutes before meals | Oral route | 1996-03-10 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1996-09-08 | Body height | 191 | cm | S |
| 1996-09-08 | Body weight | 101 | kg | S |
| 1996-09-08 | Body mass index (BMI) [Ratio] | 27.7 | kg/m2 | S |
| 1996-09-08 | Systolic blood pressure | 126 | mm[Hg] | S |
| 1996-09-08 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1996-09-08 | Heart rate | 70 | /min | S |
| 1996-09-08 | Respiratory rate | 14 | /min | S |
| 1996-09-08 | Body temperature | 36.6 | Cel | S |
| 1996-09-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
Vital signs recorded on 1996-09-08; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Alert and engaged; voice clear in conversation |
| Cardiovascular | Regular rhythm at 70 per minute. Blood pressure 128/80 mmHg supine and 120/78 mmHg after 3 minutes standing, without symptoms; no orthostatic hypotension |
| Neurological | On state: MDS-UPDRS Part III 24; Hoehn and Yahr stage 2.5; no dyskinesia |
| Gait | Recovers after two steps on the pull test; Timed Up and Go 11 seconds |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Parkinson's disease, young onset (diagnosed at 42), Hoehn and Yahr stage 2.5, without dyskinesia or motor fluctuations | active | confirmed | G20.A1 | S — Synthetic modern coding of the publicly disclosed diagnosis; the stage and the absence of motor complications are synthetic. |
| Hypokinetic dysarthria with soft speech due to Parkinson's disease | active | confirmed | R47.1 | S — Synthetic modern coding of the publicly reported speech difficulty; the severity is synthetic. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | MDS-UPDRS Parts III and IV and Hoehn and Yahr stage | Every visit | Completed today | Part III 24, unchanged; Hoehn and Yahr 2.5; Part IV: no motor complications |
| Examination | Orthostatic blood pressure, supine and after 3 minutes standing | Every visit while on dopaminergic treatment | Completed today | 128/80 mmHg supine and 120/78 mmHg at 3 minutes standing; no orthostatic hypotension |
| Medication safety | Dopaminergic regimen review for wearing-off, dyskinesia, and on-off | Every visit | Completed today | No wearing-off or dyskinesia; no change |
| Medication safety | Avoidance of dopamine-blocking drugs | Every visit | Completed today | No dopamine-blocking drugs |
| Medication safety | Medication side effects and adherence | Every visit | Completed today | No side effects or missed doses |
| Examination | Fall query and fall-risk assessment (Timed Up and Go, pull test) | Every visit | Completed today | No falls in six months; Timed Up and Go 11 seconds |
| Survey | Psychotic symptoms (hallucinations, delusions) | Every visit | Completed today | None |
| Survey | Impulse-control screen (QUIP-RS) | Every visit; mandatory on a dopamine agonist | Completed today | Negative; the screen missed at three months was done today |
| Self-management | Exercise counseling: aerobic, resistance, and balance, at least 150 minutes a week | Every visit | Completed today | About 180 minutes a week |
| Self-management | Advance care planning and goals of care | At diagnosis and at least yearly | Due | At the preventive visit next month |
| Examination | Diagnosis review against the MDS clinical diagnostic criteria | Yearly | Up to date | Confirmed by neurology six months ago; next review in the spring |
| Survey | Cognitive screen (MoCA) | At least yearly | Up to date | MoCA 27 of 30 seven months ago |
| Survey | Depression, anxiety, and apathy (PHQ-9) | At least yearly | Up to date | PHQ-9 3 seven months ago; mood good today; depression screen at the preventive visit |
| Survey | Sleep: REM sleep behavior disorder questionnaire, Epworth Sleepiness Scale, insomnia, restless legs | At least yearly | Up to date | No dream enactment or daytime sleepiness |
| Survey | Autonomic symptoms: constipation, urinary, sexual, sweating, drooling | At least yearly | Up to date | No autonomic symptoms |
| Survey | Swallowing screen (EAT-10) | At least yearly | Up to date | No choking or coughing with meals; EAT-10 due at the first visit next year |
| Examination | Speech and voice loudness | Yearly; speech therapy for speech change | Up to date | Gains maintained with daily practice |
| Referral | Physical, occupational, and speech therapy | At diagnosis, then reassessed yearly | Up to date | Physical therapy and speech therapy completed; reassess yearly |
| Laboratory | Genetic testing with counseling | Once, offered to every person with Parkinson's disease | Due | Decision at the yearly neurology review |
| Examination | Dental and oral examination | Every 6 months | Deferred | No dental examination in the six months since the first visit, a deviation from the protocol. He has no drooling, mouth pain, or chewing problems, so no harm is evident. Corrective action: a dental appointment is to be arranged at the preventive visit next month |
| Examination | Driving safety | Yearly or with a motor or cognitive change | Up to date | No change; review at the first visit next year |
| Self-management | Vaccination status (influenza, pneumococcal, zoster, COVID-19, Tdap) | Yearly, per the CDC schedule | Due | Influenza, pneumococcal, and zoster vaccines at the preventive visit next month |
| Laboratory | Routine laboratory monitoring | Not required for Parkinson's disease surveillance | Not indicated | The CMID monograph calls for no routine laboratory tests; baseline blood count, chemistry, vitamin B12, and TSH were normal at the first visit |
| Imaging | Brain MRI | If atypical parkinsonism features appear | Not indicated | No atypical features; examination stable |
| Imaging | Polysomnography for REM sleep behavior disorder | If REM sleep behavior disorder treatment is considered | Not indicated | No dream enactment |
| Medication safety | AGS Beers Criteria medication review | Yearly from age 65 | Not indicated | He is 54 |
| Examination | Deep brain stimulation programming review | Every 6 to 12 months after implantation | Not indicated | No deep brain stimulator |
Goal progress:
Guideline basis: Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee (2021); MDS clinical diagnostic criteria for Parkinson's disease (2015); The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension (2017); CMID: Clinical Monitoring Intelligence Database, Parkinson's disease monograph (2026)
Follow-up: Periodic preventive visit in four weeks, with vaccines, advance care planning, and the dental appointment. Quarterly Parkinson's disease review in three months. Next scheduled visit 1996-10-06: periodic adult preventive visit. [S]